Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 343 | 2024 | 2353 | 20.420 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 171 | 2024 | 1060 | 15.800 |
Why?
|
ErbB Receptors | 69 | 2024 | 601 | 6.640 |
Why?
|
Antineoplastic Agents | 103 | 2023 | 2038 | 6.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 95 | 2024 | 1570 | 5.730 |
Why?
|
Carcinoma, Small Cell | 105 | 2008 | 170 | 5.100 |
Why?
|
Small Cell Lung Carcinoma | 14 | 2024 | 82 | 4.680 |
Why?
|
Quinazolines | 38 | 2016 | 245 | 4.580 |
Why?
|
Protein Kinase Inhibitors | 32 | 2023 | 870 | 3.260 |
Why?
|
Paclitaxel | 31 | 2011 | 214 | 2.640 |
Why?
|
Carboplatin | 24 | 2019 | 140 | 2.320 |
Why?
|
Guanine | 11 | 2007 | 79 | 2.130 |
Why?
|
Deoxycytidine | 14 | 2004 | 163 | 2.040 |
Why?
|
Glutamates | 11 | 2007 | 58 | 1.950 |
Why?
|
Molecular Targeted Therapy | 13 | 2019 | 381 | 1.910 |
Why?
|
Neoplasm Staging | 63 | 2018 | 1285 | 1.850 |
Why?
|
Adenocarcinoma | 31 | 2017 | 895 | 1.770 |
Why?
|
Antibodies, Monoclonal | 45 | 2018 | 1359 | 1.730 |
Why?
|
Biomarkers, Tumor | 37 | 2021 | 1170 | 1.640 |
Why?
|
Humans | 525 | 2024 | 128896 | 1.630 |
Why?
|
Neoadjuvant Therapy | 9 | 2023 | 383 | 1.450 |
Why?
|
Antimetabolites, Antineoplastic | 10 | 2007 | 90 | 1.450 |
Why?
|
Taxoids | 13 | 2013 | 98 | 1.440 |
Why?
|
Receptor, ErbB-2 | 12 | 2019 | 333 | 1.430 |
Why?
|
Mutation | 30 | 2024 | 3671 | 1.410 |
Why?
|
Skin Neoplasms | 55 | 2010 | 828 | 1.370 |
Why?
|
Clinical Trials as Topic | 51 | 2024 | 1002 | 1.360 |
Why?
|
Gene Expression Regulation, Neoplastic | 24 | 2018 | 1312 | 1.330 |
Why?
|
Lymphoma | 47 | 1991 | 190 | 1.280 |
Why?
|
Combined Modality Therapy | 52 | 2023 | 1213 | 1.260 |
Why?
|
Antineoplastic Agents, Phytogenic | 10 | 2007 | 189 | 1.240 |
Why?
|
Etoposide | 26 | 2023 | 148 | 1.220 |
Why?
|
Cisplatin | 31 | 2018 | 292 | 1.150 |
Why?
|
Survival Analysis | 34 | 2019 | 1282 | 1.130 |
Why?
|
Vinblastine | 8 | 2003 | 69 | 1.120 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2023 | 626 | 1.120 |
Why?
|
Sezary Syndrome | 36 | 1996 | 43 | 1.090 |
Why?
|
Protein-Tyrosine Kinases | 10 | 2023 | 421 | 1.090 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 9 | 2010 | 42 | 1.040 |
Why?
|
Drug Resistance, Neoplasm | 19 | 2023 | 732 | 1.030 |
Why?
|
Mycosis Fungoides | 38 | 1996 | 61 | 1.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 14 | 2023 | 750 | 1.010 |
Why?
|
Aged | 142 | 2024 | 22035 | 0.990 |
Why?
|
Erlotinib Hydrochloride | 12 | 2015 | 66 | 0.990 |
Why?
|
In Situ Hybridization, Fluorescence | 22 | 2018 | 319 | 0.990 |
Why?
|
Precision Medicine | 5 | 2024 | 385 | 0.960 |
Why?
|
Bradykinin | 9 | 2005 | 46 | 0.960 |
Why?
|
Liposomes | 3 | 2024 | 163 | 0.950 |
Why?
|
Pemetrexed | 14 | 2024 | 34 | 0.940 |
Why?
|
Tumor Cells, Cultured | 31 | 2014 | 928 | 0.900 |
Why?
|
Immunotherapy | 13 | 2020 | 579 | 0.880 |
Why?
|
Middle Aged | 169 | 2024 | 30977 | 0.880 |
Why?
|
Proto-Oncogene Proteins | 15 | 2023 | 636 | 0.870 |
Why?
|
Folic Acid Antagonists | 4 | 2005 | 9 | 0.860 |
Why?
|
Angiogenesis Inhibitors | 8 | 2018 | 221 | 0.850 |
Why?
|
Prognosis | 52 | 2019 | 3787 | 0.820 |
Why?
|
Gene Dosage | 10 | 2018 | 143 | 0.800 |
Why?
|
Male | 205 | 2024 | 63146 | 0.780 |
Why?
|
Neutropenia | 12 | 2022 | 135 | 0.770 |
Why?
|
Immunohistochemistry | 25 | 2020 | 1694 | 0.770 |
Why?
|
Female | 198 | 2024 | 68162 | 0.760 |
Why?
|
Survival Rate | 23 | 2020 | 1884 | 0.740 |
Why?
|
Antigens, Neoplasm | 14 | 2009 | 308 | 0.730 |
Why?
|
Gene Amplification | 9 | 2019 | 102 | 0.720 |
Why?
|
Enzyme Inhibitors | 10 | 2016 | 827 | 0.720 |
Why?
|
Receptor Protein-Tyrosine Kinases | 10 | 2022 | 234 | 0.710 |
Why?
|
Smoking | 20 | 2019 | 1501 | 0.700 |
Why?
|
Chemotherapy, Adjuvant | 10 | 2015 | 380 | 0.680 |
Why?
|
Retirement | 1 | 2020 | 27 | 0.660 |
Why?
|
Medical Oncology | 6 | 2003 | 273 | 0.650 |
Why?
|
Brain Neoplasms | 18 | 2023 | 1137 | 0.640 |
Why?
|
Pathologists | 1 | 2019 | 15 | 0.640 |
Why?
|
Treatment Outcome | 42 | 2023 | 10239 | 0.620 |
Why?
|
Tubulin Modulators | 1 | 2018 | 9 | 0.590 |
Why?
|
Aged, 80 and over | 36 | 2024 | 7050 | 0.590 |
Why?
|
Furans | 1 | 2018 | 22 | 0.590 |
Why?
|
Sputum | 11 | 2019 | 309 | 0.580 |
Why?
|
Ketones | 1 | 2018 | 47 | 0.570 |
Why?
|
Acrylamides | 3 | 2024 | 58 | 0.570 |
Why?
|
T-Lymphocytes | 54 | 2020 | 1905 | 0.560 |
Why?
|
Randomized Controlled Trials as Topic | 20 | 2018 | 1366 | 0.560 |
Why?
|
Global Health | 3 | 2024 | 317 | 0.540 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 39 | 0.540 |
Why?
|
Aurora Kinase B | 1 | 2016 | 8 | 0.540 |
Why?
|
Thymidylate Synthase | 4 | 2005 | 12 | 0.530 |
Why?
|
Cell Division | 23 | 2007 | 800 | 0.530 |
Why?
|
Sulindac | 5 | 2007 | 17 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-met | 6 | 2020 | 75 | 0.520 |
Why?
|
Interferon Type I | 12 | 1995 | 138 | 0.510 |
Why?
|
Pneumonectomy | 3 | 2015 | 150 | 0.510 |
Why?
|
Dose-Response Relationship, Drug | 22 | 2016 | 1968 | 0.500 |
Why?
|
Awards and Prizes | 1 | 2016 | 65 | 0.500 |
Why?
|
Neoplasm Proteins | 5 | 2009 | 428 | 0.500 |
Why?
|
Organophosphates | 1 | 2016 | 114 | 0.500 |
Why?
|
Gene Rearrangement | 8 | 2018 | 151 | 0.490 |
Why?
|
Cell Cycle | 12 | 2015 | 581 | 0.490 |
Why?
|
Adult | 123 | 2024 | 35361 | 0.490 |
Why?
|
Cell Line, Tumor | 18 | 2019 | 3100 | 0.470 |
Why?
|
Precancerous Conditions | 7 | 2018 | 164 | 0.470 |
Why?
|
Chemoprevention | 5 | 2019 | 88 | 0.450 |
Why?
|
Genomics | 3 | 2020 | 715 | 0.450 |
Why?
|
Genes, erbB-2 | 8 | 2017 | 28 | 0.440 |
Why?
|
Esophagitis | 3 | 2012 | 66 | 0.430 |
Why?
|
Disease Progression | 15 | 2024 | 2603 | 0.430 |
Why?
|
Neoplasms | 10 | 2010 | 2426 | 0.430 |
Why?
|
Genes, erbB-1 | 6 | 2015 | 17 | 0.420 |
Why?
|
Cadherins | 6 | 2012 | 186 | 0.420 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2004 | 322 | 0.420 |
Why?
|
Aniline Compounds | 2 | 2024 | 95 | 0.410 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2014 | 187 | 0.400 |
Why?
|
Mass Screening | 6 | 2020 | 1121 | 0.400 |
Why?
|
Neoplasm Metastasis | 16 | 2024 | 608 | 0.390 |
Why?
|
Ribonucleotide Reductases | 4 | 2004 | 22 | 0.390 |
Why?
|
Mice, Nude | 18 | 2017 | 680 | 0.390 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2024 | 952 | 0.390 |
Why?
|
Disease-Free Survival | 11 | 2018 | 657 | 0.380 |
Why?
|
Drug Screening Assays, Antitumor | 10 | 2009 | 195 | 0.380 |
Why?
|
Melanoma | 5 | 2022 | 735 | 0.370 |
Why?
|
Neuropeptides | 6 | 1998 | 70 | 0.370 |
Why?
|
Drug Administration Schedule | 18 | 2011 | 760 | 0.370 |
Why?
|
Early Detection of Cancer | 7 | 2024 | 349 | 0.370 |
Why?
|
Pyridines | 6 | 2013 | 472 | 0.370 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2014 | 379 | 0.360 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 9 | 2019 | 264 | 0.360 |
Why?
|
Bronchi | 7 | 2018 | 253 | 0.360 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2010 | 43 | 0.350 |
Why?
|
Esophagus | 1 | 2012 | 253 | 0.340 |
Why?
|
Signal Transduction | 18 | 2017 | 4857 | 0.340 |
Why?
|
Time Factors | 33 | 2018 | 6568 | 0.340 |
Why?
|
Animals | 67 | 2019 | 34628 | 0.340 |
Why?
|
Head and Neck Neoplasms | 4 | 2009 | 527 | 0.330 |
Why?
|
Genotype | 2 | 2014 | 1834 | 0.330 |
Why?
|
Fever | 5 | 2001 | 301 | 0.330 |
Why?
|
Cell Proliferation | 9 | 2018 | 2337 | 0.320 |
Why?
|
Drug Delivery Systems | 2 | 2010 | 328 | 0.320 |
Why?
|
Predictive Value of Tests | 12 | 2014 | 1967 | 0.320 |
Why?
|
Drug Monitoring | 1 | 2010 | 193 | 0.320 |
Why?
|
Phosphorylation | 6 | 2016 | 1685 | 0.320 |
Why?
|
Biomedical Research | 5 | 2024 | 654 | 0.310 |
Why?
|
B7-H1 Antigen | 2 | 2022 | 174 | 0.310 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 3 | 2009 | 109 | 0.310 |
Why?
|
Calcium | 6 | 2002 | 1173 | 0.310 |
Why?
|
Salvage Therapy | 2 | 2007 | 136 | 0.300 |
Why?
|
Topotecan | 3 | 2024 | 12 | 0.300 |
Why?
|
Drug Therapy, Combination | 28 | 2002 | 1020 | 0.300 |
Why?
|
Xenograft Model Antitumor Assays | 8 | 2019 | 797 | 0.300 |
Why?
|
Pyrazoles | 5 | 2013 | 403 | 0.300 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2001 | 78 | 0.290 |
Why?
|
Meta-Analysis as Topic | 6 | 2017 | 163 | 0.290 |
Why?
|
Cancer Vaccines | 1 | 2009 | 164 | 0.280 |
Why?
|
Flow Cytometry | 14 | 2006 | 1146 | 0.280 |
Why?
|
Mesothelioma | 3 | 2004 | 37 | 0.280 |
Why?
|
Neoplasms, Experimental | 4 | 2002 | 168 | 0.280 |
Why?
|
Biomarkers | 4 | 2023 | 3874 | 0.280 |
Why?
|
Radiation-Sensitizing Agents | 2 | 1997 | 40 | 0.270 |
Why?
|
Leukemia | 16 | 2018 | 228 | 0.270 |
Why?
|
Receptors, KIR | 2 | 2018 | 96 | 0.270 |
Why?
|
Camptothecin | 5 | 2017 | 106 | 0.270 |
Why?
|
Oligopeptides | 4 | 2005 | 256 | 0.270 |
Why?
|
Protease Inhibitors | 2 | 2004 | 104 | 0.260 |
Why?
|
ras Proteins | 7 | 2014 | 150 | 0.260 |
Why?
|
Gene Expression Profiling | 9 | 2016 | 1694 | 0.260 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2018 | 195 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2023 | 359 | 0.250 |
Why?
|
Interferons | 7 | 1995 | 187 | 0.250 |
Why?
|
Mice | 32 | 2019 | 16543 | 0.250 |
Why?
|
Bradykinin Receptor Antagonists | 2 | 2002 | 3 | 0.250 |
Why?
|
Lung | 14 | 2023 | 3925 | 0.250 |
Why?
|
Thrombocytopenia | 8 | 2001 | 187 | 0.250 |
Why?
|
Carcinoma in Situ | 4 | 2019 | 45 | 0.250 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2015 | 210 | 0.250 |
Why?
|
Recombinant Proteins | 14 | 1998 | 1304 | 0.240 |
Why?
|
Apoptosis | 9 | 2018 | 2481 | 0.240 |
Why?
|
Topoisomerase I Inhibitors | 3 | 2024 | 17 | 0.240 |
Why?
|
Antigens, Surface | 10 | 1988 | 149 | 0.240 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2002 | 80 | 0.240 |
Why?
|
Genes, ras | 5 | 2015 | 97 | 0.240 |
Why?
|
Breast Neoplasms | 9 | 2018 | 2112 | 0.230 |
Why?
|
Tankyrases | 2 | 2016 | 13 | 0.230 |
Why?
|
Indium Radioisotopes | 5 | 1991 | 13 | 0.230 |
Why?
|
Asymptomatic Infections | 1 | 2024 | 23 | 0.230 |
Why?
|
Radiotherapy Dosage | 13 | 2007 | 249 | 0.230 |
Why?
|
Neovascularization, Pathologic | 7 | 2015 | 293 | 0.230 |
Why?
|
Boronic Acids | 1 | 2004 | 37 | 0.230 |
Why?
|
Committee Membership | 1 | 2003 | 2 | 0.220 |
Why?
|
Leukemia, Lymphoid | 7 | 1987 | 27 | 0.220 |
Why?
|
Transplantation, Heterologous | 9 | 2006 | 190 | 0.220 |
Why?
|
Volatile Organic Compounds | 3 | 2013 | 54 | 0.220 |
Why?
|
Organophosphorus Compounds | 1 | 2004 | 76 | 0.220 |
Why?
|
Organizational Objectives | 1 | 2003 | 73 | 0.220 |
Why?
|
Liver Neoplasms | 7 | 2015 | 637 | 0.210 |
Why?
|
United States | 22 | 2020 | 13975 | 0.210 |
Why?
|
Pyrazines | 1 | 2004 | 88 | 0.210 |
Why?
|
Retrospective Studies | 19 | 2024 | 14546 | 0.210 |
Why?
|
Anticarcinogenic Agents | 1 | 2004 | 76 | 0.210 |
Why?
|
Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 588 | 0.210 |
Why?
|
HTLV-I Infections | 2 | 1996 | 22 | 0.210 |
Why?
|
Delivery of Health Care | 1 | 2010 | 896 | 0.210 |
Why?
|
Follow-Up Studies | 18 | 2019 | 4917 | 0.210 |
Why?
|
Neoplasm Transplantation | 11 | 2004 | 254 | 0.210 |
Why?
|
Receptor, ErbB-3 | 3 | 2009 | 45 | 0.200 |
Why?
|
Bronchoscopy | 10 | 2019 | 215 | 0.200 |
Why?
|
Doxorubicin | 22 | 2002 | 319 | 0.200 |
Why?
|
Cluster Analysis | 4 | 2016 | 479 | 0.200 |
Why?
|
Penicillins | 22 | 1969 | 58 | 0.200 |
Why?
|
Drug Synergism | 6 | 2016 | 354 | 0.200 |
Why?
|
Airway Obstruction | 2 | 2003 | 157 | 0.200 |
Why?
|
Organoplatinum Compounds | 3 | 2006 | 40 | 0.200 |
Why?
|
Iodine Radioisotopes | 5 | 1992 | 142 | 0.200 |
Why?
|
Anti-Bacterial Agents | 23 | 2001 | 1701 | 0.200 |
Why?
|
Growth Substances | 4 | 2000 | 155 | 0.200 |
Why?
|
Biopsy | 12 | 2023 | 1093 | 0.200 |
Why?
|
Carcinoma, Bronchogenic | 10 | 1984 | 19 | 0.190 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2002 | 55 | 0.190 |
Why?
|
Roxithromycin | 1 | 2001 | 1 | 0.190 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 60 | 0.190 |
Why?
|
Iloprost | 2 | 2012 | 46 | 0.190 |
Why?
|
DNA, Neoplasm | 8 | 2013 | 162 | 0.190 |
Why?
|
Societies | 1 | 2001 | 37 | 0.190 |
Why?
|
Research Design | 7 | 2008 | 1038 | 0.190 |
Why?
|
Neprilysin | 2 | 1998 | 48 | 0.180 |
Why?
|
Biological Products | 2 | 2023 | 202 | 0.180 |
Why?
|
Quality of Life | 5 | 2022 | 2706 | 0.180 |
Why?
|
Biomarkers, Pharmacological | 2 | 2019 | 27 | 0.180 |
Why?
|
Diarrhea | 1 | 2022 | 179 | 0.180 |
Why?
|
Cell Line | 24 | 2000 | 2759 | 0.180 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2014 | 136 | 0.180 |
Why?
|
Cell Cycle Checkpoints | 2 | 2018 | 95 | 0.180 |
Why?
|
Pleural Neoplasms | 2 | 2016 | 23 | 0.180 |
Why?
|
Artificial Intelligence | 1 | 2023 | 233 | 0.180 |
Why?
|
Prospective Studies | 15 | 2023 | 7060 | 0.180 |
Why?
|
Antibiotic Prophylaxis | 1 | 2001 | 104 | 0.180 |
Why?
|
Smoking Prevention | 1 | 2001 | 163 | 0.170 |
Why?
|
Programmed Cell Death 1 Receptor | 2 | 2022 | 225 | 0.170 |
Why?
|
DNA Copy Number Variations | 2 | 2018 | 172 | 0.170 |
Why?
|
Societies, Medical | 2 | 2003 | 760 | 0.170 |
Why?
|
Ki-67 Antigen | 4 | 2015 | 109 | 0.170 |
Why?
|
Age Factors | 7 | 2016 | 3133 | 0.170 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 4 | 2012 | 19 | 0.170 |
Why?
|
Oncogenes | 4 | 2016 | 111 | 0.170 |
Why?
|
Patient Participation | 1 | 2003 | 402 | 0.170 |
Why?
|
GTP Phosphohydrolases | 3 | 2015 | 76 | 0.170 |
Why?
|
Carcinoma, Large Cell | 4 | 2012 | 16 | 0.160 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 224 | 0.160 |
Why?
|
Vaping | 1 | 2020 | 57 | 0.160 |
Why?
|
Epidermal Growth Factor | 4 | 2013 | 170 | 0.160 |
Why?
|
Lymph Nodes | 17 | 1991 | 458 | 0.160 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2012 | 206 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 6 | 2016 | 861 | 0.160 |
Why?
|
Aminoquinolines | 1 | 2019 | 21 | 0.160 |
Why?
|
Antibodies, Viral | 12 | 2024 | 598 | 0.160 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 100 | 0.160 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2020 | 91 | 0.150 |
Why?
|
Friends | 1 | 2019 | 51 | 0.150 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 1523 | 0.150 |
Why?
|
Trastuzumab | 4 | 2002 | 97 | 0.150 |
Why?
|
Structure-Activity Relationship | 6 | 2018 | 539 | 0.150 |
Why?
|
Homeodomain Proteins | 3 | 2010 | 480 | 0.150 |
Why?
|
Gene Expression | 6 | 2008 | 1476 | 0.150 |
Why?
|
DNA Methylation | 3 | 2018 | 600 | 0.150 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2004 | 211 | 0.150 |
Why?
|
Wasting Syndrome | 1 | 1998 | 11 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 3 | 2011 | 2270 | 0.150 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 2 | 1996 | 13 | 0.150 |
Why?
|
History, 21st Century | 1 | 2019 | 182 | 0.150 |
Why?
|
Receptor, IGF Type 1 | 2 | 2010 | 63 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2004 | 72 | 0.150 |
Why?
|
Caspase 3 | 2 | 2018 | 241 | 0.150 |
Why?
|
Interferon-alpha | 4 | 1995 | 191 | 0.150 |
Why?
|
Immunoenzyme Techniques | 5 | 2014 | 210 | 0.150 |
Why?
|
Tumor Escape | 1 | 2018 | 38 | 0.150 |
Why?
|
Proto-Oncogenes | 2 | 2014 | 29 | 0.150 |
Why?
|
Forecasting | 4 | 2003 | 363 | 0.150 |
Why?
|
Young Adult | 10 | 2020 | 12286 | 0.140 |
Why?
|
Smoking Cessation | 3 | 2019 | 409 | 0.140 |
Why?
|
Lung Injury | 1 | 2020 | 214 | 0.140 |
Why?
|
Cranial Irradiation | 2 | 1995 | 68 | 0.140 |
Why?
|
CpG Islands | 1 | 2018 | 151 | 0.140 |
Why?
|
Genetic Association Studies | 2 | 2017 | 356 | 0.140 |
Why?
|
Folic Acid | 4 | 2002 | 182 | 0.140 |
Why?
|
Lung Diseases | 6 | 2015 | 755 | 0.140 |
Why?
|
Vitamin B 12 | 3 | 2002 | 120 | 0.140 |
Why?
|
Mutagenesis, Insertional | 1 | 2017 | 66 | 0.140 |
Why?
|
Multiple Myeloma | 5 | 1997 | 120 | 0.140 |
Why?
|
Bone Marrow | 10 | 1992 | 262 | 0.140 |
Why?
|
Clinical Protocols | 1 | 2019 | 255 | 0.140 |
Why?
|
Cyclophosphamide | 19 | 2001 | 232 | 0.140 |
Why?
|
Cetuximab | 4 | 2008 | 93 | 0.140 |
Why?
|
Drug Evaluation | 15 | 1992 | 79 | 0.140 |
Why?
|
Receptors, KIR2DL3 | 1 | 2016 | 9 | 0.140 |
Why?
|
Receptors, KIR2DL4 | 1 | 2016 | 4 | 0.140 |
Why?
|
Proportional Hazards Models | 6 | 2016 | 1221 | 0.140 |
Why?
|
Palliative Care | 6 | 2003 | 712 | 0.140 |
Why?
|
HLA Antigens | 4 | 1988 | 236 | 0.140 |
Why?
|
Receptors, KIR2DL1 | 1 | 2016 | 18 | 0.140 |
Why?
|
Receptors, KIR3DL1 | 1 | 2016 | 17 | 0.140 |
Why?
|
Patients | 1 | 2018 | 167 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2017 | 508 | 0.140 |
Why?
|
Interleukin-2 | 3 | 1995 | 427 | 0.130 |
Why?
|
Polyploidy | 1 | 2016 | 18 | 0.130 |
Why?
|
DNA Mutational Analysis | 6 | 2017 | 391 | 0.130 |
Why?
|
Genes, myc | 1 | 2016 | 48 | 0.130 |
Why?
|
RNA, Messenger | 7 | 2014 | 2700 | 0.130 |
Why?
|
Chemoradiotherapy | 1 | 2018 | 207 | 0.130 |
Why?
|
Pleural Effusion, Malignant | 1 | 2016 | 8 | 0.130 |
Why?
|
Patient Selection | 7 | 2008 | 671 | 0.130 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2001 | 72 | 0.130 |
Why?
|
Translocation, Genetic | 1 | 2016 | 97 | 0.130 |
Why?
|
Bone Neoplasms | 4 | 2015 | 227 | 0.130 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1996 | 14 | 0.130 |
Why?
|
Computational Biology | 2 | 2018 | 587 | 0.130 |
Why?
|
Genetic Therapy | 4 | 2015 | 292 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2016 | 91 | 0.130 |
Why?
|
Empathy | 2 | 2009 | 172 | 0.130 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 1996 | 28 | 0.130 |
Why?
|
Dimerization | 3 | 2002 | 189 | 0.130 |
Why?
|
Molecular Biology | 1 | 2016 | 54 | 0.130 |
Why?
|
Cohort Studies | 9 | 2019 | 5394 | 0.120 |
Why?
|
Radiosurgery | 2 | 2014 | 316 | 0.120 |
Why?
|
Membrane Proteins | 3 | 2015 | 1100 | 0.120 |
Why?
|
Peritoneal Neoplasms | 1 | 2016 | 83 | 0.120 |
Why?
|
Nerve Tissue Proteins | 1 | 1999 | 568 | 0.120 |
Why?
|
Disease Models, Animal | 5 | 2016 | 3994 | 0.120 |
Why?
|
Tumor Burden | 1 | 2016 | 284 | 0.120 |
Why?
|
Ifosfamide | 4 | 2008 | 33 | 0.120 |
Why?
|
Remission Induction | 7 | 2019 | 269 | 0.120 |
Why?
|
Sex Factors | 6 | 2015 | 1947 | 0.120 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 203 | 0.120 |
Why?
|
Patient-Specific Modeling | 1 | 2014 | 39 | 0.120 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 149 | 0.120 |
Why?
|
Up-Regulation | 3 | 2002 | 848 | 0.120 |
Why?
|
Amino Acid Sequence | 6 | 1999 | 2047 | 0.120 |
Why?
|
HIV | 1 | 1996 | 223 | 0.120 |
Why?
|
Prevalence | 4 | 2023 | 2540 | 0.120 |
Why?
|
Biosensing Techniques | 2 | 2013 | 115 | 0.110 |
Why?
|
Administration, Oral | 5 | 2012 | 783 | 0.110 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2015 | 84 | 0.110 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 2019 | 383 | 0.110 |
Why?
|
Correction of Hearing Impairment | 1 | 2014 | 15 | 0.110 |
Why?
|
Tomography, Spiral Computed | 1 | 2013 | 27 | 0.110 |
Why?
|
Attitude to Computers | 1 | 2014 | 27 | 0.110 |
Why?
|
Transcription Factors | 3 | 2010 | 1634 | 0.110 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 50 | 0.110 |
Why?
|
Lymph Node Excision | 1 | 2015 | 166 | 0.110 |
Why?
|
Persons With Hearing Impairments | 1 | 2014 | 23 | 0.110 |
Why?
|
Interferon-gamma | 3 | 1995 | 759 | 0.110 |
Why?
|
PUVA Therapy | 3 | 1990 | 6 | 0.110 |
Why?
|
Genetic Testing | 2 | 2011 | 424 | 0.110 |
Why?
|
Multiplex Polymerase Chain Reaction | 1 | 2014 | 51 | 0.110 |
Why?
|
Activities of Daily Living | 1 | 2016 | 382 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 3 | 2013 | 83 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 5 | 2015 | 418 | 0.100 |
Why?
|
Physicians | 2 | 2019 | 846 | 0.100 |
Why?
|
Deltaretrovirus Infections | 3 | 1988 | 6 | 0.100 |
Why?
|
Retroviridae | 9 | 1983 | 96 | 0.100 |
Why?
|
Wnt Proteins | 2 | 2012 | 127 | 0.100 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 778 | 0.100 |
Why?
|
Hearing Aids | 1 | 2014 | 74 | 0.100 |
Why?
|
Hypogonadism | 1 | 2013 | 82 | 0.100 |
Why?
|
Hyperplasia | 2 | 2011 | 171 | 0.100 |
Why?
|
DNA | 6 | 1983 | 1406 | 0.100 |
Why?
|
Loss of Heterozygosity | 2 | 2002 | 44 | 0.100 |
Why?
|
Radioimmunotherapy | 1 | 1992 | 14 | 0.100 |
Why?
|
Software | 1 | 2017 | 611 | 0.100 |
Why?
|
Neurosecretory Systems | 2 | 2017 | 31 | 0.100 |
Why?
|
Polymerase Chain Reaction | 3 | 2006 | 1045 | 0.100 |
Why?
|
Genetic Variation | 1 | 2017 | 935 | 0.100 |
Why?
|
Risk Assessment | 5 | 2010 | 3286 | 0.100 |
Why?
|
Risk Factors | 9 | 2019 | 9792 | 0.090 |
Why?
|
Androgens | 1 | 2013 | 173 | 0.090 |
Why?
|
Prostatic Neoplasms | 5 | 2018 | 995 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 957 | 0.090 |
Why?
|
Meningeal Neoplasms | 4 | 1986 | 88 | 0.090 |
Why?
|
Benzamides | 1 | 2012 | 191 | 0.090 |
Why?
|
Molecular Sequence Data | 6 | 1999 | 2842 | 0.090 |
Why?
|
Histones | 1 | 2016 | 584 | 0.090 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2002 | 50 | 0.090 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2011 | 55 | 0.090 |
Why?
|
Deltaretrovirus | 6 | 1986 | 12 | 0.090 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2015 | 81 | 0.090 |
Why?
|
MAP Kinase Kinase 1 | 3 | 2015 | 76 | 0.090 |
Why?
|
Antibiotics, Antitubercular | 11 | 1961 | 37 | 0.090 |
Why?
|
Cervical Vertebrae | 2 | 2002 | 130 | 0.090 |
Why?
|
Antibody Formation | 2 | 2022 | 284 | 0.090 |
Why?
|
Gold | 1 | 2011 | 116 | 0.090 |
Why?
|
Cognition | 2 | 2009 | 1093 | 0.090 |
Why?
|
Zinc Finger E-box-Binding Homeobox 1 | 2 | 2010 | 24 | 0.090 |
Why?
|
Hearing Loss | 1 | 2014 | 208 | 0.090 |
Why?
|
Molecular Structure | 2 | 2005 | 469 | 0.090 |
Why?
|
Isoenzymes | 2 | 2004 | 303 | 0.090 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.090 |
Why?
|
Radionuclide Imaging | 13 | 1991 | 126 | 0.090 |
Why?
|
Transcriptome | 1 | 2016 | 871 | 0.090 |
Why?
|
Mucins | 1 | 1990 | 71 | 0.090 |
Why?
|
Dermatologic Agents | 11 | 1961 | 66 | 0.080 |
Why?
|
Stomach Neoplasms | 3 | 1982 | 97 | 0.080 |
Why?
|
Tuberculosis | 19 | 1970 | 271 | 0.080 |
Why?
|
Indium | 5 | 1987 | 9 | 0.080 |
Why?
|
Radiography | 9 | 2002 | 863 | 0.080 |
Why?
|
Placebos | 3 | 2019 | 203 | 0.080 |
Why?
|
Random Allocation | 7 | 2017 | 351 | 0.080 |
Why?
|
Neoplasm Invasiveness | 3 | 2015 | 479 | 0.080 |
Why?
|
Expressed Emotion | 1 | 2009 | 18 | 0.080 |
Why?
|
Tumor Virus Infections | 3 | 1984 | 46 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2010 | 102 | 0.080 |
Why?
|
Tocopherols | 1 | 2009 | 22 | 0.080 |
Why?
|
Isotretinoin | 1 | 2009 | 23 | 0.080 |
Why?
|
Testosterone | 1 | 2013 | 382 | 0.080 |
Why?
|
Antibodies, Neoplasm | 4 | 2001 | 35 | 0.080 |
Why?
|
Vasodilator Agents | 1 | 2011 | 325 | 0.080 |
Why?
|
Catheter Ablation | 1 | 2012 | 324 | 0.080 |
Why?
|
Central Nervous System Diseases | 2 | 1983 | 68 | 0.080 |
Why?
|
Blotting, Western | 6 | 2014 | 1188 | 0.080 |
Why?
|
Staphylococcal Infections | 7 | 1981 | 385 | 0.080 |
Why?
|
Kanamycin | 6 | 1970 | 8 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 985 | 0.080 |
Why?
|
Wounds, Nonpenetrating | 2 | 2002 | 283 | 0.080 |
Why?
|
Spinal Cord Neoplasms | 4 | 1986 | 39 | 0.080 |
Why?
|
Fluorenes | 1 | 2009 | 39 | 0.080 |
Why?
|
Mitogen-Activated Protein Kinases | 2 | 2002 | 311 | 0.080 |
Why?
|
MicroRNAs | 2 | 2012 | 668 | 0.080 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2008 | 65 | 0.080 |
Why?
|
Rats | 6 | 2005 | 5236 | 0.080 |
Why?
|
Podophyllotoxin | 3 | 2003 | 7 | 0.080 |
Why?
|
Aneuploidy | 5 | 2010 | 92 | 0.080 |
Why?
|
Cell Survival | 5 | 2013 | 1082 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2023 | 3042 | 0.080 |
Why?
|
Vincristine | 13 | 1989 | 109 | 0.080 |
Why?
|
Amides | 1 | 2009 | 91 | 0.070 |
Why?
|
Rats, Nude | 4 | 2003 | 28 | 0.070 |
Why?
|
Multigene Family | 2 | 2006 | 197 | 0.070 |
Why?
|
Lymphatic Metastasis | 6 | 2020 | 312 | 0.070 |
Why?
|
Mice, Inbred BALB C | 4 | 2004 | 1230 | 0.070 |
Why?
|
Social Perception | 1 | 2009 | 103 | 0.070 |
Why?
|
National Institutes of Health (U.S.) | 4 | 1996 | 122 | 0.070 |
Why?
|
Antisocial Personality Disorder | 1 | 2009 | 162 | 0.070 |
Why?
|
Sample Size | 1 | 2008 | 117 | 0.070 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 641 | 0.070 |
Why?
|
Kinetics | 8 | 1991 | 1619 | 0.070 |
Why?
|
Multivariate Analysis | 5 | 2016 | 1504 | 0.070 |
Why?
|
Nanoparticles | 1 | 2011 | 358 | 0.070 |
Why?
|
Chromosome Aberrations | 6 | 1993 | 148 | 0.070 |
Why?
|
Models, Statistical | 1 | 1991 | 626 | 0.070 |
Why?
|
Bombesin | 3 | 1994 | 12 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 764 | 0.070 |
Why?
|
Inflammation | 1 | 2018 | 2694 | 0.070 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2002 | 173 | 0.070 |
Why?
|
Immunoglobulins | 2 | 1985 | 158 | 0.070 |
Why?
|
Fibroblast Growth Factors | 1 | 2008 | 171 | 0.070 |
Why?
|
Exons | 2 | 2019 | 330 | 0.070 |
Why?
|
Epithelial Cells | 4 | 2007 | 1059 | 0.070 |
Why?
|
Receptors, Growth Factor | 2 | 1997 | 55 | 0.070 |
Why?
|
Incidence | 3 | 2018 | 2634 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 339 | 0.070 |
Why?
|
Epitopes | 3 | 1986 | 466 | 0.070 |
Why?
|
Psychological Tests | 1 | 2007 | 133 | 0.070 |
Why?
|
Congresses as Topic | 3 | 2020 | 217 | 0.070 |
Why?
|
Radioisotopes | 4 | 1987 | 31 | 0.070 |
Why?
|
Databases, Genetic | 2 | 2018 | 226 | 0.070 |
Why?
|
Bevacizumab | 1 | 2007 | 130 | 0.070 |
Why?
|
Mesoderm | 1 | 2007 | 139 | 0.070 |
Why?
|
Cytokines | 4 | 1997 | 1995 | 0.060 |
Why?
|
Radioimmunoassay | 3 | 1986 | 169 | 0.060 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1987 | 63 | 0.060 |
Why?
|
Tegafur | 1 | 2005 | 3 | 0.060 |
Why?
|
Immunologic Factors | 3 | 1996 | 227 | 0.060 |
Why?
|
Platinum Compounds | 1 | 2005 | 10 | 0.060 |
Why?
|
Uracil | 1 | 2005 | 29 | 0.060 |
Why?
|
Teniposide | 2 | 2003 | 3 | 0.060 |
Why?
|
Aging | 2 | 2014 | 1767 | 0.060 |
Why?
|
Receptors, Cell Surface | 2 | 2001 | 379 | 0.060 |
Why?
|
Area Under Curve | 2 | 2005 | 285 | 0.060 |
Why?
|
In Situ Nick-End Labeling | 2 | 2003 | 125 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2008 | 528 | 0.060 |
Why?
|
beta 2-Microglobulin | 1 | 1985 | 49 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2014 | 1264 | 0.060 |
Why?
|
Resting Phase, Cell Cycle | 1 | 2005 | 15 | 0.060 |
Why?
|
Adolescent | 10 | 2020 | 20197 | 0.060 |
Why?
|
PTEN Phosphohydrolase | 1 | 2006 | 148 | 0.060 |
Why?
|
Anti-Infective Agents | 4 | 2001 | 246 | 0.060 |
Why?
|
Drug Resistance | 5 | 2006 | 166 | 0.060 |
Why?
|
G1 Phase | 1 | 2005 | 70 | 0.060 |
Why?
|
Matrix Metalloproteinase Inhibitors | 2 | 2005 | 15 | 0.060 |
Why?
|
Affect | 1 | 2007 | 287 | 0.060 |
Why?
|
Radiation, Ionizing | 1 | 2005 | 75 | 0.060 |
Why?
|
Binding Sites, Antibody | 1 | 1984 | 42 | 0.060 |
Why?
|
Regression Analysis | 3 | 2003 | 987 | 0.060 |
Why?
|
Injections, Subcutaneous | 3 | 2002 | 145 | 0.060 |
Why?
|
Selenium | 2 | 2004 | 37 | 0.060 |
Why?
|
Drug Therapy | 5 | 1983 | 77 | 0.060 |
Why?
|
Animal Welfare | 1 | 2004 | 13 | 0.060 |
Why?
|
Bortezomib | 1 | 2004 | 44 | 0.060 |
Why?
|
Data Collection | 1 | 2007 | 652 | 0.060 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 484 | 0.060 |
Why?
|
Radiotherapy | 6 | 1994 | 186 | 0.060 |
Why?
|
Biological Therapy | 1 | 2004 | 30 | 0.060 |
Why?
|
Retroviridae Infections | 4 | 1985 | 46 | 0.060 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 159 | 0.060 |
Why?
|
Karyotyping | 6 | 1996 | 107 | 0.060 |
Why?
|
Retinoids | 1 | 2004 | 33 | 0.060 |
Why?
|
Planning Techniques | 1 | 2003 | 15 | 0.060 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 73 | 0.060 |
Why?
|
Decision Making, Organizational | 1 | 2003 | 26 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 1976 | 113 | 0.060 |
Why?
|
Nucleocapsid | 1 | 2023 | 18 | 0.060 |
Why?
|
Immunologic Tests | 1 | 2023 | 19 | 0.060 |
Why?
|
Surveys and Questionnaires | 4 | 2014 | 5355 | 0.050 |
Why?
|
Biotechnology | 1 | 2004 | 42 | 0.050 |
Why?
|
Lymphocytes | 1 | 1985 | 369 | 0.050 |
Why?
|
Vitamin E | 1 | 2004 | 118 | 0.050 |
Why?
|
Vaccination | 2 | 2022 | 1350 | 0.050 |
Why?
|
Necrosis | 1 | 2004 | 234 | 0.050 |
Why?
|
Transfection | 1 | 2006 | 904 | 0.050 |
Why?
|
Immunotoxins | 2 | 1995 | 45 | 0.050 |
Why?
|
Nervous System Neoplasms | 1 | 1983 | 2 | 0.050 |
Why?
|
Methotrexate | 11 | 1986 | 248 | 0.050 |
Why?
|
Diagnostic Imaging | 2 | 2009 | 327 | 0.050 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 172 | 0.050 |
Why?
|
Radiation Tolerance | 1 | 2004 | 97 | 0.050 |
Why?
|
Meninges | 4 | 1982 | 37 | 0.050 |
Why?
|
Pilot Projects | 3 | 2012 | 1545 | 0.050 |
Why?
|
Proteomics | 3 | 2007 | 985 | 0.050 |
Why?
|
Methylmalonic Acid | 1 | 2002 | 62 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 1988 | 422 | 0.050 |
Why?
|
Fruit | 1 | 2003 | 131 | 0.050 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2017 | 190 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2002 | 811 | 0.050 |
Why?
|
Farnesyltranstransferase | 1 | 2002 | 35 | 0.050 |
Why?
|
Pandemics | 2 | 2022 | 1516 | 0.050 |
Why?
|
Vegetables | 1 | 2003 | 146 | 0.050 |
Why?
|
Metaplasia | 2 | 2018 | 54 | 0.050 |
Why?
|
Automation | 1 | 2002 | 81 | 0.050 |
Why?
|
Streptozocin | 3 | 1983 | 16 | 0.050 |
Why?
|
Autoradiography | 3 | 1981 | 76 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2002 | 34 | 0.050 |
Why?
|
Parents | 2 | 2009 | 1301 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2007 | 772 | 0.050 |
Why?
|
Infusion Pumps | 1 | 2002 | 31 | 0.050 |
Why?
|
Skin | 7 | 1987 | 737 | 0.050 |
Why?
|
Tetrazolium Salts | 1 | 2002 | 19 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2002 | 106 | 0.050 |
Why?
|
Homocysteine | 1 | 2002 | 150 | 0.050 |
Why?
|
SEER Program | 1 | 2003 | 208 | 0.050 |
Why?
|
Hypercalcemia | 4 | 1986 | 21 | 0.050 |
Why?
|
Peptides | 3 | 2001 | 902 | 0.050 |
Why?
|
Proteome | 1 | 2006 | 423 | 0.050 |
Why?
|
Antigen-Antibody Complex | 4 | 1986 | 84 | 0.050 |
Why?
|
Mechlorethamine | 3 | 1994 | 63 | 0.050 |
Why?
|
Metalloendopeptidases | 2 | 2002 | 58 | 0.050 |
Why?
|
Testis | 1 | 2002 | 143 | 0.050 |
Why?
|
Mediastinal Neoplasms | 1 | 2002 | 39 | 0.050 |
Why?
|
Indoles | 1 | 2024 | 378 | 0.050 |
Why?
|
Infusions, Intravenous | 3 | 2004 | 395 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2003 | 287 | 0.050 |
Why?
|
Ciprofloxacin | 1 | 2001 | 30 | 0.050 |
Why?
|
Thiazoles | 1 | 2002 | 115 | 0.050 |
Why?
|
Dietary Supplements | 2 | 2004 | 533 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2017 | 318 | 0.050 |
Why?
|
Leukopenia | 5 | 1995 | 27 | 0.050 |
Why?
|
Pedigree | 3 | 2000 | 491 | 0.050 |
Why?
|
Pyrimidines | 1 | 2024 | 444 | 0.050 |
Why?
|
Kinins | 1 | 2001 | 3 | 0.050 |
Why?
|
Endpoint Determination | 1 | 2001 | 76 | 0.050 |
Why?
|
Fluorescence | 1 | 2001 | 159 | 0.050 |
Why?
|
Double-Blind Method | 2 | 2019 | 1858 | 0.050 |
Why?
|
HIV Infections | 1 | 1996 | 2696 | 0.050 |
Why?
|
Neoplastic Cells, Circulating | 2 | 1984 | 67 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1985 | 699 | 0.050 |
Why?
|
Leukemia, Plasma Cell | 1 | 1980 | 4 | 0.040 |
Why?
|
Paraproteinemias | 1 | 1980 | 4 | 0.040 |
Why?
|
Hypergammaglobulinemia | 1 | 1980 | 9 | 0.040 |
Why?
|
Central Nervous System | 1 | 2023 | 254 | 0.040 |
Why?
|
Plasmacytoma | 1 | 1980 | 16 | 0.040 |
Why?
|
Lymphoproliferative Disorders | 3 | 1988 | 53 | 0.040 |
Why?
|
Cell Count | 3 | 1996 | 316 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2015 | 1840 | 0.040 |
Why?
|
Endothelium, Vascular | 2 | 2004 | 917 | 0.040 |
Why?
|
Microscopy, Fluorescence | 1 | 2002 | 404 | 0.040 |
Why?
|
Microtubules | 1 | 2003 | 252 | 0.040 |
Why?
|
Receptors, Interleukin-2 | 2 | 1995 | 65 | 0.040 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 50 | 0.040 |
Why?
|
Telomerase | 1 | 2002 | 228 | 0.040 |
Why?
|
Antioxidants | 1 | 2004 | 557 | 0.040 |
Why?
|
Ploidies | 4 | 2003 | 17 | 0.040 |
Why?
|
Receptors, Virus | 1 | 2020 | 81 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2020 | 359 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2000 | 86 | 0.040 |
Why?
|
Lipoxygenase Inhibitors | 1 | 1999 | 37 | 0.040 |
Why?
|
Observer Variation | 1 | 2020 | 321 | 0.040 |
Why?
|
Algorithms | 3 | 2015 | 1626 | 0.040 |
Why?
|
ELAV Proteins | 1 | 1999 | 14 | 0.040 |
Why?
|
Gene Transfer Techniques | 2 | 1998 | 159 | 0.040 |
Why?
|
Carcinoembryonic Antigen | 1 | 1979 | 42 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 2000 | 211 | 0.040 |
Why?
|
Sepsis | 3 | 1981 | 561 | 0.040 |
Why?
|
Stomach Diseases | 1 | 1979 | 20 | 0.040 |
Why?
|
Streptomycin | 8 | 1954 | 16 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2000 | 859 | 0.040 |
Why?
|
Electrons | 4 | 1989 | 78 | 0.040 |
Why?
|
Light | 1 | 2001 | 355 | 0.040 |
Why?
|
Stomach | 1 | 1979 | 109 | 0.040 |
Why?
|
Antibodies | 3 | 1990 | 392 | 0.040 |
Why?
|
gamma Catenin | 1 | 2018 | 14 | 0.040 |
Why?
|
Protein Kinase C | 1 | 2000 | 258 | 0.040 |
Why?
|
Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
|
Spinal Cord Injuries | 1 | 2002 | 190 | 0.040 |
Why?
|
Smokers | 1 | 2019 | 135 | 0.040 |
Why?
|
Administration, Topical | 2 | 1994 | 148 | 0.040 |
Why?
|
History, 20th Century | 2 | 1996 | 294 | 0.040 |
Why?
|
HIV Wasting Syndrome | 1 | 1998 | 4 | 0.040 |
Why?
|
Teaching | 1 | 2020 | 209 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2012 | 3334 | 0.040 |
Why?
|
Bronchial Diseases | 1 | 2018 | 39 | 0.040 |
Why?
|
Carcinoma | 4 | 2001 | 214 | 0.040 |
Why?
|
Tissue Distribution | 5 | 1990 | 295 | 0.040 |
Why?
|
Postoperative Care | 1 | 2000 | 246 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2013 | 730 | 0.040 |
Why?
|
Hematologic Diseases | 3 | 1995 | 61 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2012 | 575 | 0.040 |
Why?
|
Gastrin-Releasing Peptide | 2 | 1996 | 7 | 0.040 |
Why?
|
Models, Molecular | 2 | 2018 | 1477 | 0.040 |
Why?
|
Skin Diseases | 2 | 1979 | 143 | 0.040 |
Why?
|
Organoids | 1 | 2019 | 100 | 0.040 |
Why?
|
Pneumonia | 6 | 1968 | 612 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2017 | 4 | 0.040 |
Why?
|
Genes, p53 | 1 | 1998 | 69 | 0.040 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2017 | 16 | 0.040 |
Why?
|
Type C Phospholipases | 1 | 1998 | 72 | 0.040 |
Why?
|
Communicable Diseases | 4 | 1964 | 141 | 0.040 |
Why?
|
Preoperative Care | 1 | 2000 | 343 | 0.040 |
Why?
|
North America | 1 | 1998 | 289 | 0.040 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 181 | 0.040 |
Why?
|
Web Browser | 1 | 2017 | 12 | 0.030 |
Why?
|
Drug Resistance, Multiple | 1 | 1997 | 21 | 0.030 |
Why?
|
Receptors, Notch | 1 | 2017 | 85 | 0.030 |
Why?
|
Demecolcine | 1 | 1976 | 2 | 0.030 |
Why?
|
Endocarditis, Subacute Bacterial | 3 | 1964 | 3 | 0.030 |
Why?
|
Mice, SCID | 1 | 2017 | 340 | 0.030 |
Why?
|
Bronchial Neoplasms | 1 | 1996 | 14 | 0.030 |
Why?
|
Risk | 5 | 2001 | 866 | 0.030 |
Why?
|
Platinum | 1 | 2016 | 43 | 0.030 |
Why?
|
B-Lymphocytes | 5 | 1986 | 813 | 0.030 |
Why?
|
Maximum Tolerated Dose | 2 | 2007 | 195 | 0.030 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 1996 | 137 | 0.030 |
Why?
|
Tuberculosis, Ocular | 5 | 1954 | 8 | 0.030 |
Why?
|
Registries | 1 | 2024 | 1916 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2003 | 2668 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 155 | 0.030 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 170 | 0.030 |
Why?
|
Mitogens | 4 | 1998 | 58 | 0.030 |
Why?
|
Carcinogenesis | 1 | 2017 | 200 | 0.030 |
Why?
|
Endocarditis | 3 | 1964 | 36 | 0.030 |
Why?
|
Receptors, Cytokine | 1 | 1996 | 35 | 0.030 |
Why?
|
Drug Stability | 1 | 1996 | 150 | 0.030 |
Why?
|
RNA-Binding Proteins | 1 | 1999 | 382 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 579 | 0.030 |
Why?
|
Diet | 1 | 2003 | 1205 | 0.030 |
Why?
|
Premedication | 1 | 1995 | 40 | 0.030 |
Why?
|
Comorbidity | 2 | 2016 | 1542 | 0.030 |
Why?
|
Analgesics, Non-Narcotic | 1 | 1997 | 123 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 234 | 0.030 |
Why?
|
Growth Inhibitors | 2 | 2002 | 43 | 0.030 |
Why?
|
Rabbits | 10 | 2005 | 757 | 0.030 |
Why?
|
Meningitis | 4 | 1974 | 81 | 0.030 |
Why?
|
Hematopoiesis | 1 | 1976 | 184 | 0.030 |
Why?
|
Cross-Linking Reagents | 1 | 1996 | 200 | 0.030 |
Why?
|
Pathology, Molecular | 1 | 2015 | 25 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 474 | 0.030 |
Why?
|
GTP-Binding Proteins | 1 | 1996 | 156 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1995 | 82 | 0.030 |
Why?
|
Interferon-beta | 1 | 1995 | 88 | 0.030 |
Why?
|
Military Medicine | 1 | 1996 | 61 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2003 | 2767 | 0.030 |
Why?
|
HLA-A Antigens | 2 | 1985 | 53 | 0.030 |
Why?
|
Diphtheria Toxin | 1 | 1995 | 56 | 0.030 |
Why?
|
HLA-C Antigens | 2 | 1985 | 35 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 1996 | 101 | 0.030 |
Why?
|
Guinea Pigs | 3 | 2005 | 158 | 0.030 |
Why?
|
Bone Marrow Transplantation | 2 | 1986 | 267 | 0.030 |
Why?
|
Wnt Signaling Pathway | 1 | 2016 | 164 | 0.030 |
Why?
|
Photopheresis | 1 | 1994 | 9 | 0.030 |
Why?
|
HLA-B Antigens | 2 | 1985 | 62 | 0.030 |
Why?
|
Whole-Body Irradiation | 3 | 1991 | 76 | 0.030 |
Why?
|
Antigens, Viral | 4 | 1984 | 181 | 0.030 |
Why?
|
Colorado | 2 | 2014 | 4443 | 0.030 |
Why?
|
Glioblastoma | 1 | 2018 | 311 | 0.030 |
Why?
|
Mitomycin | 2 | 1992 | 32 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 93 | 0.030 |
Why?
|
Cholecystokinin | 1 | 1994 | 14 | 0.030 |
Why?
|
Proteins | 1 | 2000 | 945 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 576 | 0.030 |
Why?
|
Methoxsalen | 1 | 1994 | 4 | 0.030 |
Why?
|
Substance P | 1 | 1994 | 44 | 0.030 |
Why?
|
Ultraviolet Therapy | 1 | 1994 | 18 | 0.030 |
Why?
|
gamma-Globulins | 2 | 1965 | 18 | 0.030 |
Why?
|
Research | 2 | 1994 | 413 | 0.030 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 1994 | 8 | 0.030 |
Why?
|
Contraindications | 1 | 1994 | 90 | 0.030 |
Why?
|
Glioma | 1 | 2018 | 347 | 0.030 |
Why?
|
Texas | 1 | 2014 | 227 | 0.030 |
Why?
|
Pyridazines | 1 | 2014 | 48 | 0.030 |
Why?
|
Odds Ratio | 1 | 2016 | 1019 | 0.030 |
Why?
|
Serum Albumin | 2 | 2013 | 145 | 0.030 |
Why?
|
Micrococcus | 3 | 1958 | 4 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 3 | 1992 | 32 | 0.030 |
Why?
|
Staphylococcus | 3 | 1970 | 74 | 0.030 |
Why?
|
Fibroblasts | 1 | 1998 | 946 | 0.030 |
Why?
|
Safety | 1 | 1995 | 325 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2000 | 1423 | 0.030 |
Why?
|
Endoscopy | 1 | 2015 | 268 | 0.030 |
Why?
|
DNA Fingerprinting | 1 | 2013 | 25 | 0.030 |
Why?
|
Muscle Denervation | 1 | 1973 | 12 | 0.030 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2013 | 53 | 0.030 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2014 | 326 | 0.030 |
Why?
|
Ileum | 2 | 2005 | 113 | 0.030 |
Why?
|
Urinary Tract Infections | 3 | 1970 | 144 | 0.030 |
Why?
|
In Vitro Techniques | 5 | 2002 | 1061 | 0.030 |
Why?
|
Maintenance Chemotherapy | 1 | 2013 | 22 | 0.030 |
Why?
|
Imidazoles | 1 | 2014 | 224 | 0.030 |
Why?
|
Consensus | 1 | 2016 | 644 | 0.030 |
Why?
|
Solid Phase Microextraction | 1 | 2012 | 6 | 0.030 |
Why?
|
Radiation Dosage | 2 | 1992 | 159 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2023 | 3348 | 0.030 |
Why?
|
Treatment Failure | 1 | 1994 | 345 | 0.030 |
Why?
|
Auditory Perception | 1 | 2014 | 109 | 0.030 |
Why?
|
DNA Primers | 2 | 2009 | 522 | 0.030 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 1992 | 31 | 0.030 |
Why?
|
Neuromuscular Junction | 1 | 1973 | 56 | 0.030 |
Why?
|
Chromosome Banding | 4 | 1996 | 21 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 2013 | 177 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2012 | 126 | 0.020 |
Why?
|
International Cooperation | 2 | 2003 | 172 | 0.020 |
Why?
|
Breath Tests | 1 | 2012 | 91 | 0.020 |
Why?
|
Mitomycins | 2 | 1984 | 4 | 0.020 |
Why?
|
Hearing | 1 | 2014 | 134 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2013 | 101 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1995 | 640 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 4 | 1954 | 131 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 427 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 1992 | 6 | 0.020 |
Why?
|
Ionomycin | 1 | 1992 | 24 | 0.020 |
Why?
|
Species Specificity | 2 | 2005 | 566 | 0.020 |
Why?
|
Ricin | 1 | 1991 | 8 | 0.020 |
Why?
|
Probability | 3 | 2009 | 313 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 522 | 0.020 |
Why?
|
Nanostructures | 1 | 2013 | 98 | 0.020 |
Why?
|
Immunization, Passive | 2 | 2001 | 82 | 0.020 |
Why?
|
Chromosome Deletion | 2 | 1982 | 104 | 0.020 |
Why?
|
Properdin | 2 | 1962 | 8 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2013 | 158 | 0.020 |
Why?
|
Radiometry | 1 | 1992 | 48 | 0.020 |
Why?
|
Follicle Stimulating Hormone | 1 | 2013 | 238 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 503 | 0.020 |
Why?
|
Liver | 5 | 1987 | 1832 | 0.020 |
Why?
|
Fatigue | 2 | 2005 | 319 | 0.020 |
Why?
|
Ambulatory Care | 1 | 1995 | 509 | 0.020 |
Why?
|
Logistic Models | 1 | 2016 | 1963 | 0.020 |
Why?
|
Immunosorbent Techniques | 1 | 1991 | 18 | 0.020 |
Why?
|
Laboratories | 2 | 1963 | 102 | 0.020 |
Why?
|
Pyridones | 1 | 2013 | 158 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 4 | 1959 | 135 | 0.020 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 1982 | 11 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1990 | 226 | 0.020 |
Why?
|
Lomustine | 7 | 1986 | 14 | 0.020 |
Why?
|
Iceland | 1 | 2011 | 10 | 0.020 |
Why?
|
Drug Hypersensitivity | 2 | 1970 | 92 | 0.020 |
Why?
|
Japan | 2 | 2009 | 100 | 0.020 |
Why?
|
Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 13 | 0.020 |
Why?
|
Vimentin | 1 | 2011 | 50 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 729 | 0.020 |
Why?
|
Spain | 1 | 2011 | 36 | 0.020 |
Why?
|
Perception | 1 | 2014 | 336 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1991 | 56 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 822 | 0.020 |
Why?
|
Adsorption | 1 | 1991 | 138 | 0.020 |
Why?
|
Netherlands | 1 | 2011 | 77 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2013 | 319 | 0.020 |
Why?
|
Zinc Finger E-box Binding Homeobox 2 | 1 | 2010 | 5 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2014 | 326 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2015 | 5032 | 0.020 |
Why?
|
Motor Neurons | 1 | 1973 | 236 | 0.020 |
Why?
|
Photochemotherapy | 2 | 1980 | 28 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2010 | 55 | 0.020 |
Why?
|
Megakaryocytes | 3 | 1980 | 32 | 0.020 |
Why?
|
Databases, Factual | 1 | 1996 | 1289 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2002 | 1435 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 113 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1990 | 150 | 0.020 |
Why?
|
Thyroid Neoplasms | 1 | 1994 | 308 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 2 | 1980 | 13 | 0.020 |
Why?
|
Base Sequence | 2 | 2009 | 2157 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 2 | 1988 | 20 | 0.020 |
Why?
|
Clone Cells | 3 | 1985 | 257 | 0.020 |
Why?
|
Nervous System Diseases | 3 | 1985 | 260 | 0.020 |
Why?
|
Carrier Proteins | 1 | 1994 | 728 | 0.020 |
Why?
|
Nicotinic Acids | 3 | 1954 | 6 | 0.020 |
Why?
|
Hemagglutination Tests | 2 | 1964 | 7 | 0.020 |
Why?
|
Niacin | 3 | 1954 | 19 | 0.020 |
Why?
|
Mitosis | 3 | 1981 | 177 | 0.020 |
Why?
|
Down-Regulation | 1 | 1992 | 637 | 0.020 |
Why?
|
Calcitriol | 2 | 1986 | 56 | 0.020 |
Why?
|
Bacterial Infections | 2 | 2001 | 236 | 0.020 |
Why?
|
Deafness | 1 | 1970 | 79 | 0.020 |
Why?
|
Diethylstilbestrol | 2 | 1986 | 9 | 0.020 |
Why?
|
Isoniazid | 3 | 1954 | 59 | 0.020 |
Why?
|
Personality Inventory | 1 | 2009 | 138 | 0.020 |
Why?
|
Infusions, Parenteral | 2 | 1986 | 39 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2009 | 159 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 1991 | 308 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2014 | 727 | 0.020 |
Why?
|
Ovary | 1 | 1990 | 212 | 0.020 |
Why?
|
Histocytochemistry | 3 | 1983 | 78 | 0.020 |
Why?
|
Thoracic Surgery | 1 | 2010 | 133 | 0.020 |
Why?
|
Tuberculosis, Meningeal | 4 | 1964 | 6 | 0.020 |
Why?
|
Herpes Simplex | 2 | 1987 | 94 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 424 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2002 | 2530 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 420 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 2 | 1987 | 392 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2008 | 295 | 0.020 |
Why?
|
Pulmonary Fibrosis | 2 | 1986 | 381 | 0.020 |
Why?
|
Tetracycline | 2 | 1958 | 12 | 0.020 |
Why?
|
Bone Marrow Cells | 3 | 1980 | 291 | 0.020 |
Why?
|
New South Wales | 1 | 2007 | 14 | 0.020 |
Why?
|
Rosette Formation | 2 | 1987 | 16 | 0.020 |
Why?
|
Queensland | 1 | 2007 | 40 | 0.020 |
Why?
|
Ampicillin | 2 | 1965 | 14 | 0.020 |
Why?
|
Immunophenotyping | 2 | 2001 | 310 | 0.020 |
Why?
|
Eye | 3 | 1954 | 104 | 0.020 |
Why?
|
Protein Synthesis Inhibitors | 2 | 1958 | 41 | 0.020 |
Why?
|
Actuarial Analysis | 1 | 1987 | 25 | 0.020 |
Why?
|
Body Fluids | 2 | 1964 | 61 | 0.020 |
Why?
|
Remission, Spontaneous | 4 | 1980 | 38 | 0.020 |
Why?
|
Fluorouracil | 2 | 1998 | 198 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2010 | 400 | 0.020 |
Why?
|
Pneumonia, Pneumococcal | 2 | 1960 | 41 | 0.020 |
Why?
|
Procarbazine | 5 | 1986 | 8 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 1989 | 342 | 0.020 |
Why?
|
Dyspnea | 2 | 1986 | 236 | 0.020 |
Why?
|
Hydrocortisone | 2 | 1981 | 300 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2007 | 185 | 0.020 |
Why?
|
Genome, Human | 1 | 2009 | 393 | 0.020 |
Why?
|
Calcitonin | 1 | 1986 | 24 | 0.020 |
Why?
|
Nucleotidases | 2 | 1985 | 7 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 1986 | 89 | 0.020 |
Why?
|
Genome | 1 | 2009 | 276 | 0.020 |
Why?
|
California | 1 | 2008 | 402 | 0.020 |
Why?
|
Reference Values | 1 | 2008 | 791 | 0.020 |
Why?
|
Bacillus | 2 | 1957 | 16 | 0.020 |
Why?
|
Phosphates | 2 | 1958 | 168 | 0.020 |
Why?
|
Sulfadiazine | 1 | 1966 | 4 | 0.020 |
Why?
|
DNA Repair | 1 | 2008 | 208 | 0.020 |
Why?
|
Nocardia Infections | 1 | 1966 | 8 | 0.020 |
Why?
|
Gram-Positive Bacteria | 2 | 1957 | 45 | 0.020 |
Why?
|
Antigen-Antibody Reactions | 1 | 1966 | 51 | 0.020 |
Why?
|
Radioisotope Dilution Technique | 1 | 1986 | 13 | 0.020 |
Why?
|
Farmer's Lung | 1 | 1965 | 3 | 0.020 |
Why?
|
Immunoglobulin Idiotypes | 1 | 1986 | 27 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1986 | 82 | 0.020 |
Why?
|
Insecta | 2 | 1957 | 66 | 0.020 |
Why?
|
Vomiting | 3 | 2001 | 128 | 0.020 |
Why?
|
Erythromycin | 2 | 1958 | 25 | 0.020 |
Why?
|
Mice, Inbred A | 1 | 2005 | 49 | 0.020 |
Why?
|
Child | 4 | 2009 | 20824 | 0.020 |
Why?
|
Deoxyribonucleosides | 1 | 1985 | 2 | 0.020 |
Why?
|
Urea | 1 | 1966 | 75 | 0.020 |
Why?
|
Databases, Nucleic Acid | 1 | 2005 | 34 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1986 | 131 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 1986 | 108 | 0.020 |
Why?
|
Freezing | 1 | 1986 | 86 | 0.020 |
Why?
|
Peritonitis | 1 | 1966 | 81 | 0.020 |
Why?
|
Child, Preschool | 3 | 2007 | 10457 | 0.020 |
Why?
|
DNA Damage | 1 | 2008 | 377 | 0.020 |
Why?
|
Mathematics | 1 | 1986 | 103 | 0.020 |
Why?
|
Cell Movement | 2 | 1981 | 932 | 0.020 |
Why?
|
Blood | 1 | 1985 | 99 | 0.020 |
Why?
|
HLA-B35 Antigen | 1 | 1985 | 3 | 0.020 |
Why?
|
HLA-B8 Antigen | 1 | 1985 | 14 | 0.020 |
Why?
|
Enzymes | 1 | 2005 | 65 | 0.020 |
Why?
|
Phenylalanine | 1 | 2005 | 60 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2008 | 1283 | 0.020 |
Why?
|
Mycoses | 1 | 1966 | 70 | 0.020 |
Why?
|
Bleomycin | 2 | 1978 | 241 | 0.020 |
Why?
|
Carcinogens | 1 | 2005 | 109 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 1985 | 191 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1985 | 87 | 0.020 |
Why?
|
Genes, MHC Class II | 1 | 1985 | 72 | 0.020 |
Why?
|
Myeloma Proteins | 1 | 1984 | 14 | 0.020 |
Why?
|
Lymphokines | 1 | 1985 | 126 | 0.020 |
Why?
|
Haemophilus | 1 | 1965 | 7 | 0.010 |
Why?
|
Melphalan | 1 | 1984 | 30 | 0.010 |
Why?
|
Exanthema | 1 | 2005 | 76 | 0.010 |
Why?
|
Endocytosis | 1 | 1986 | 162 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1985 | 122 | 0.010 |
Why?
|
Carmustine | 1 | 1984 | 50 | 0.010 |
Why?
|
Viral Proteins | 3 | 1981 | 329 | 0.010 |
Why?
|
Tyrosine | 1 | 2005 | 219 | 0.010 |
Why?
|
Monocytes | 2 | 1985 | 553 | 0.010 |
Why?
|
Syndrome | 3 | 1984 | 342 | 0.010 |
Why?
|
Endocarditis, Bacterial | 1 | 1965 | 42 | 0.010 |
Why?
|
Cross Reactions | 1 | 1984 | 129 | 0.010 |
Why?
|
Nausea | 2 | 2001 | 104 | 0.010 |
Why?
|
Psychology, Child | 1 | 2004 | 37 | 0.010 |
Why?
|
Hemagglutination | 1 | 1964 | 8 | 0.010 |
Why?
|
Bronchopneumonia | 1 | 1964 | 5 | 0.010 |
Why?
|
DNA, Recombinant | 1 | 1984 | 46 | 0.010 |
Why?
|
Acute Disease | 2 | 1984 | 978 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 1334 | 0.010 |
Why?
|
DNA Replication | 1 | 2005 | 225 | 0.010 |
Why?
|
Acetaminophen | 1 | 1987 | 255 | 0.010 |
Why?
|
Nephritis, Interstitial | 1 | 1984 | 13 | 0.010 |
Why?
|
Expectorants | 1 | 1964 | 24 | 0.010 |
Why?
|
Nephrosis, Lipoid | 1 | 1984 | 10 | 0.010 |
Why?
|
Hypersensitivity, Delayed | 1 | 1983 | 28 | 0.010 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 289 | 0.010 |
Why?
|
Densitometry | 2 | 1980 | 32 | 0.010 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2003 | 15 | 0.010 |
Why?
|
Cell Transformation, Viral | 2 | 1984 | 28 | 0.010 |
Why?
|
Chromosomes | 2 | 1982 | 100 | 0.010 |
Why?
|
Prednisone | 1 | 1984 | 241 | 0.010 |
Why?
|
Paraneoplastic Syndromes | 1 | 1983 | 12 | 0.010 |
Why?
|
Muscles | 3 | 1982 | 322 | 0.010 |
Why?
|
3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 17 | 0.010 |
Why?
|
Toxicology | 1 | 1964 | 42 | 0.010 |
Why?
|
Virus Diseases | 1 | 1966 | 207 | 0.010 |
Why?
|
Growth Hormone | 2 | 1954 | 96 | 0.010 |
Why?
|
Biopsy, Needle | 2 | 1982 | 191 | 0.010 |
Why?
|
Vital Capacity | 1 | 2004 | 285 | 0.010 |
Why?
|
Cloxacillin | 1 | 1963 | 1 | 0.010 |
Why?
|
Transfer Factor | 1 | 1983 | 1 | 0.010 |
Why?
|
Vitamins | 1 | 2004 | 171 | 0.010 |
Why?
|
Tuberculosis, Miliary | 3 | 1964 | 5 | 0.010 |
Why?
|
Furunculosis | 1 | 1962 | 1 | 0.010 |
Why?
|
Sex Ratio | 1 | 1983 | 14 | 0.010 |
Why?
|
Razoxane | 1 | 1982 | 1 | 0.010 |
Why?
|
Receptors, Bradykinin | 1 | 2002 | 5 | 0.010 |
Why?
|
Leukapheresis | 1 | 1983 | 21 | 0.010 |
Why?
|
Thymosin | 2 | 1980 | 5 | 0.010 |
Why?
|
Allergy and Immunology | 1 | 1964 | 60 | 0.010 |
Why?
|
Antilymphocyte Serum | 1 | 1983 | 63 | 0.010 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2003 | 89 | 0.010 |
Why?
|
Cell Membrane | 2 | 2002 | 728 | 0.010 |
Why?
|
Drainage | 1 | 1964 | 162 | 0.010 |
Why?
|
Pneumococcal Infections | 2 | 1956 | 110 | 0.010 |
Why?
|
Mycobacterium tuberculosis | 2 | 1957 | 312 | 0.010 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 1983 | 166 | 0.010 |
Why?
|
Nucleoside Deaminases | 1 | 1982 | 2 | 0.010 |
Why?
|
Pentosyltransferases | 1 | 1982 | 6 | 0.010 |
Why?
|
Purine-Nucleoside Phosphorylase | 1 | 1982 | 5 | 0.010 |
Why?
|
Autopsy | 1 | 1983 | 89 | 0.010 |
Why?
|
Lymphocyte Activation | 3 | 1983 | 1091 | 0.010 |
Why?
|
Streptococcal Infections | 1 | 1965 | 145 | 0.010 |
Why?
|
Cells, Cultured | 7 | 1985 | 4048 | 0.010 |
Why?
|
Adenosine Deaminase | 1 | 1982 | 26 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2004 | 509 | 0.010 |
Why?
|
Bacteriophages | 2 | 1961 | 93 | 0.010 |
Why?
|
Keratins | 1 | 2003 | 176 | 0.010 |
Why?
|
Cysteine | 1 | 1964 | 190 | 0.010 |
Why?
|
Immunity, Cellular | 2 | 1984 | 266 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2004 | 182 | 0.010 |
Why?
|
Agglutinins | 1 | 1962 | 2 | 0.010 |
Why?
|
Umbilical Cord | 1 | 2002 | 84 | 0.010 |
Why?
|
Clinical Enzyme Tests | 1 | 1982 | 11 | 0.010 |
Why?
|
Aggression | 1 | 2004 | 192 | 0.010 |
Why?
|
Phosphopyruvate Hydratase | 1 | 1982 | 27 | 0.010 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1982 | 7 | 0.010 |
Why?
|
Receptors, Fc | 1 | 1982 | 49 | 0.010 |
Why?
|
Abdominal Neoplasms | 1 | 1982 | 32 | 0.010 |
Why?
|
Manipulation, Spinal | 1 | 2002 | 7 | 0.010 |
Why?
|
Caspases | 1 | 2003 | 248 | 0.010 |
Why?
|
Rectal Diseases | 1 | 1981 | 19 | 0.010 |
Why?
|
Complement System Proteins | 2 | 1962 | 307 | 0.010 |
Why?
|
Bone Resorption | 1 | 1982 | 77 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2002 | 115 | 0.010 |
Why?
|
Sulfonamides | 2 | 1955 | 494 | 0.010 |
Why?
|
Herpesvirus 4, Human | 2 | 1980 | 153 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 1983 | 213 | 0.010 |
Why?
|
Immune System | 1 | 1983 | 175 | 0.010 |
Why?
|
Oculomotor Muscles | 2 | 1951 | 39 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2006 | 1194 | 0.010 |
Why?
|
CD52 Antigen | 1 | 2001 | 4 | 0.010 |
Why?
|
Spinal Fractures | 1 | 2002 | 81 | 0.010 |
Why?
|
Alemtuzumab | 1 | 2001 | 15 | 0.010 |
Why?
|
Zymosan | 1 | 1961 | 65 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1983 | 267 | 0.010 |
Why?
|
Glasgow Coma Scale | 1 | 2002 | 170 | 0.010 |
Why?
|
Phenotype | 4 | 1984 | 3059 | 0.010 |
Why?
|
APUD Cells | 1 | 1980 | 1 | 0.010 |
Why?
|
Furocoumarins | 1 | 1980 | 8 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2001 | 273 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2000 | 38 | 0.010 |
Why?
|
Polysaccharides | 1 | 1961 | 84 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2000 | 140 | 0.010 |
Why?
|
Amyloidosis | 1 | 1980 | 39 | 0.010 |
Why?
|
Hospitals, Chronic Disease | 2 | 1958 | 2 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1980 | 80 | 0.010 |
Why?
|
Intestinal Neoplasms | 1 | 1980 | 28 | 0.010 |
Why?
|
Biological Assay | 1 | 2001 | 117 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2001 | 115 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1980 | 41 | 0.010 |
Why?
|
Cytological Techniques | 1 | 1980 | 25 | 0.010 |
Why?
|
Piperazines | 1 | 1982 | 326 | 0.010 |
Why?
|
Leukocytes | 2 | 1984 | 301 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2002 | 319 | 0.010 |
Why?
|
Health Resources | 1 | 2001 | 121 | 0.010 |
Why?
|
Hypersensitivity | 1 | 1964 | 277 | 0.010 |
Why?
|
Anemia | 1 | 2001 | 155 | 0.010 |
Why?
|
Antiviral Agents | 1 | 1966 | 708 | 0.010 |
Why?
|
Soft Tissue Neoplasms | 1 | 1981 | 111 | 0.010 |
Why?
|
Bacteremia | 1 | 1962 | 190 | 0.010 |
Why?
|
Disease Management | 1 | 1964 | 594 | 0.010 |
Why?
|
Brain | 3 | 1985 | 2592 | 0.010 |
Why?
|
Thymus Hormones | 1 | 1979 | 1 | 0.010 |
Why?
|
Influenza, Human | 1 | 1985 | 603 | 0.010 |
Why?
|
Carcinogens, Environmental | 1 | 1979 | 7 | 0.010 |
Why?
|
Range of Motion, Articular | 1 | 2002 | 386 | 0.010 |
Why?
|
Stomach Ulcer | 1 | 1979 | 10 | 0.010 |
Why?
|
Gastroscopy | 1 | 1979 | 18 | 0.010 |
Why?
|
Joint Instability | 1 | 2002 | 181 | 0.010 |
Why?
|
Duodenal Ulcer | 1 | 1979 | 11 | 0.010 |
Why?
|
Spinal Cord | 1 | 1982 | 360 | 0.010 |
Why?
|
Osteoporosis | 1 | 1982 | 233 | 0.010 |
Why?
|
History, 19th Century | 1 | 1979 | 56 | 0.010 |
Why?
|
Glycoproteins | 1 | 2001 | 340 | 0.010 |
Why?
|
Semustine | 1 | 1978 | 1 | 0.010 |
Why?
|
Neuroblastoma | 1 | 1980 | 152 | 0.010 |
Why?
|
Hybridomas | 2 | 1994 | 234 | 0.010 |
Why?
|
Demeclocycline | 1 | 1978 | 3 | 0.010 |
Why?
|
Spinal Cord Compression | 1 | 1978 | 19 | 0.010 |
Why?
|
Blood Platelets | 2 | 1984 | 369 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2002 | 615 | 0.010 |
Why?
|
Protein Biosynthesis | 1 | 2000 | 409 | 0.010 |
Why?
|
Antigens, CD | 1 | 2001 | 479 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 1998 | 28 | 0.010 |
Why?
|
Phospholipase C beta | 1 | 1998 | 27 | 0.010 |
Why?
|
Chloramphenicol | 1 | 1958 | 9 | 0.010 |
Why?
|
Levamisole | 1 | 1998 | 19 | 0.010 |
Why?
|
Vasopressins | 1 | 1978 | 64 | 0.010 |
Why?
|
Gastritis | 1 | 1979 | 98 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1979 | 139 | 0.010 |
Why?
|
Antibody Specificity | 3 | 1983 | 185 | 0.010 |
Why?
|
Practice Patterns, Physicians' | 1 | 2006 | 1281 | 0.010 |
Why?
|
Estradiol | 1 | 1981 | 494 | 0.010 |
Why?
|
Cell Separation | 3 | 1986 | 311 | 0.010 |
Why?
|
Hormones, Ectopic | 1 | 1977 | 2 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 1980 | 377 | 0.010 |
Why?
|
Occupational Diseases | 1 | 1979 | 142 | 0.010 |
Why?
|
Amantadine | 2 | 1968 | 6 | 0.010 |
Why?
|
Thoracotomy | 1 | 1997 | 75 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 1997 | 67 | 0.010 |
Why?
|
Vinca Alkaloids | 1 | 1976 | 4 | 0.010 |
Why?
|
Genetic Markers | 1 | 1998 | 335 | 0.010 |
Why?
|
Capsules | 1 | 1957 | 37 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1977 | 142 | 0.010 |
Why?
|
Penicillin V | 1 | 1956 | 3 | 0.010 |
Why?
|
Cephalosporins | 2 | 1968 | 39 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 1994 | 834 | 0.010 |
Why?
|
Cycloserine | 1 | 1956 | 5 | 0.010 |
Why?
|
Gentamicins | 2 | 1968 | 51 | 0.010 |
Why?
|
Pregnancy | 1 | 1989 | 6247 | 0.010 |
Why?
|
Colchicine | 1 | 1976 | 26 | 0.010 |
Why?
|
Novobiocin | 1 | 1956 | 5 | 0.010 |
Why?
|
Gallium Radioisotopes | 1 | 1975 | 14 | 0.010 |
Why?
|
Maryland | 1 | 1996 | 43 | 0.010 |
Why?
|
Computer Communication Networks | 1 | 1996 | 32 | 0.010 |
Why?
|
Sulfisoxazole | 1 | 1955 | 1 | 0.010 |
Why?
|
Arthritis | 1 | 1957 | 113 | 0.010 |
Why?
|
Herpes Zoster | 1 | 1980 | 349 | 0.010 |
Why?
|
Glycopeptides | 1 | 1996 | 44 | 0.010 |
Why?
|
Laparoscopy | 1 | 1980 | 452 | 0.010 |
Why?
|
Cerebrospinal Fluid | 1 | 1976 | 94 | 0.010 |
Why?
|
Cyclic AMP | 1 | 1996 | 230 | 0.010 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 1997 | 642 | 0.010 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 1994 | 5 | 0.010 |
Why?
|
Streptococcus pneumoniae | 1 | 1956 | 157 | 0.010 |
Why?
|
Portal System | 1 | 1953 | 12 | 0.010 |
Why?
|
Phlebitis | 1 | 1953 | 11 | 0.010 |
Why?
|
Leucomycins | 1 | 1953 | 1 | 0.010 |
Why?
|
Dogs | 2 | 1987 | 372 | 0.010 |
Why?
|
Respiratory Function Tests | 2 | 1986 | 596 | 0.010 |
Why?
|
Veins | 1 | 1953 | 60 | 0.010 |
Why?
|
Heart Neoplasms | 1 | 1994 | 50 | 0.010 |
Why?
|
Isomerism | 1 | 1953 | 48 | 0.010 |
Why?
|
Thyroid Gland | 1 | 1994 | 94 | 0.010 |
Why?
|
Gallamine Triethiodide | 1 | 1973 | 1 | 0.010 |
Why?
|
Edrophonium | 1 | 1973 | 2 | 0.010 |
Why?
|
Organ Specificity | 1 | 1994 | 296 | 0.010 |
Why?
|
Pulmonary Alveoli | 1 | 1996 | 403 | 0.010 |
Why?
|
Disease | 1 | 1953 | 95 | 0.010 |
Why?
|
Sciatic Nerve | 1 | 1973 | 59 | 0.010 |
Why?
|
Human Growth Hormone | 1 | 1953 | 44 | 0.010 |
Why?
|
Cats | 1 | 1973 | 211 | 0.010 |
Why?
|
Chromosomes, Human, 1-3 | 2 | 1982 | 2 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 1992 | 89 | 0.010 |
Why?
|
Meningitis, Pneumococcal | 1 | 1952 | 7 | 0.010 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 1992 | 12 | 0.010 |
Why?
|
Cytotoxicity, Immunologic | 2 | 1983 | 214 | 0.010 |
Why?
|
Appendicitis | 1 | 1953 | 133 | 0.010 |
Why?
|
Electric Stimulation | 1 | 1973 | 266 | 0.010 |
Why?
|
Recurrence | 3 | 1980 | 1013 | 0.010 |
Why?
|
Models, Biological | 1 | 1979 | 1702 | 0.010 |
Why?
|
Hormones | 1 | 1952 | 139 | 0.010 |
Why?
|
Evaluation Studies as Topic | 2 | 1982 | 175 | 0.010 |
Why?
|
Erythrocytes | 1 | 1976 | 667 | 0.010 |
Why?
|
Perfusion | 1 | 1992 | 191 | 0.010 |
Why?
|
Vestibulocochlear Nerve | 1 | 1970 | 7 | 0.010 |
Why?
|
Klebsiella | 1 | 1970 | 4 | 0.010 |
Why?
|
Blood Cell Count | 2 | 1981 | 54 | 0.010 |
Why?
|
Organ of Corti | 1 | 1970 | 14 | 0.010 |
Why?
|
Synaptic Transmission | 1 | 1973 | 258 | 0.010 |
Why?
|
Chlortetracycline | 1 | 1950 | 4 | 0.010 |
Why?
|
Insulin | 1 | 1981 | 2311 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1970 | 67 | 0.010 |
Why?
|
Injections | 1 | 1991 | 174 | 0.010 |
Why?
|
Enterobacteriaceae Infections | 1 | 1970 | 37 | 0.010 |
Why?
|
Culture Media | 2 | 1981 | 168 | 0.010 |
Why?
|
Kidney | 2 | 1984 | 1330 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1982 | 417 | 0.010 |
Why?
|
Paralysis | 1 | 1970 | 71 | 0.010 |
Why?
|
Promegestone | 1 | 1989 | 33 | 0.010 |
Why?
|
Muscle Contraction | 1 | 1973 | 426 | 0.010 |
Why?
|
Action Potentials | 1 | 1973 | 463 | 0.010 |
Why?
|
Formaldehyde | 1 | 1989 | 57 | 0.010 |
Why?
|
Chickenpox | 1 | 1950 | 100 | 0.010 |
Why?
|
Neuromuscular Diseases | 1 | 1970 | 106 | 0.000 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1968 | 11 | 0.000 |
Why?
|
Thrombocythemia, Essential | 1 | 1988 | 7 | 0.000 |
Why?
|
Polymyxins | 1 | 1968 | 9 | 0.000 |
Why?
|
Immunoglobulin Isotypes | 1 | 1987 | 35 | 0.000 |
Why?
|
Hepatic Insufficiency | 1 | 1947 | 4 | 0.000 |
Why?
|
Whole-Body Counting | 1 | 1987 | 6 | 0.000 |
Why?
|
Lysosomes | 1 | 1968 | 139 | 0.000 |
Why?
|
Propidium | 1 | 1986 | 8 | 0.000 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1988 | 110 | 0.000 |
Why?
|
Medroxyprogesterone | 1 | 1986 | 10 | 0.000 |
Why?
|
Kidney Diseases | 1 | 1970 | 366 | 0.000 |
Why?
|
Medroxyprogesterone Acetate | 1 | 1986 | 35 | 0.000 |
Why?
|
Infant | 1 | 1980 | 8994 | 0.000 |
Why?
|
Coloring Agents | 1 | 1986 | 78 | 0.000 |
Why?
|
Orchiectomy | 1 | 1986 | 64 | 0.000 |
Why?
|
Cephaloridine | 1 | 1966 | 1 | 0.000 |
Why?
|
Immunodiffusion | 1 | 1965 | 15 | 0.000 |
Why?
|
Immunoglobulin M | 1 | 1987 | 268 | 0.000 |
Why?
|
Sulfanilamides | 2 | 1955 | 2 | 0.000 |
Why?
|
Polymers | 1 | 1989 | 475 | 0.000 |
Why?
|
Spleen | 1 | 1987 | 518 | 0.000 |
Why?
|
Immunization | 1 | 1987 | 416 | 0.000 |
Why?
|
Tuberculosis, Renal | 1 | 1964 | 1 | 0.000 |
Why?
|
Pathology | 1 | 1964 | 15 | 0.000 |
Why?
|
Death, Sudden | 1 | 1964 | 25 | 0.000 |
Why?
|
Canada | 1 | 1965 | 355 | 0.000 |
Why?
|
Memory Disorders | 1 | 1985 | 156 | 0.000 |
Why?
|
Purines | 1 | 1985 | 170 | 0.000 |
Why?
|
Molecular Weight | 1 | 1984 | 332 | 0.000 |
Why?
|
Polyethylene Glycols | 1 | 1989 | 598 | 0.000 |
Why?
|
Blood Cells | 1 | 1984 | 39 | 0.000 |
Why?
|
Urticaria | 1 | 1984 | 42 | 0.000 |
Why?
|
Cell Differentiation | 2 | 1985 | 1854 | 0.000 |
Why?
|
West Indies | 1 | 1983 | 4 | 0.000 |
Why?
|
Leukemia, Hairy Cell | 1 | 1983 | 6 | 0.000 |
Why?
|
Leucovorin | 1 | 1983 | 69 | 0.000 |
Why?
|
Alabama | 1 | 1983 | 37 | 0.000 |
Why?
|
Aspartate Aminotransferases | 1 | 1983 | 86 | 0.000 |
Why?
|
Georgia | 1 | 1983 | 79 | 0.000 |
Why?
|
Florida | 1 | 1983 | 91 | 0.000 |
Why?
|
Respiratory Tract Infections | 1 | 1968 | 372 | 0.000 |
Why?
|
Skin Tests | 1 | 1983 | 126 | 0.000 |
Why?
|
Warfarin | 1 | 1984 | 150 | 0.000 |
Why?
|
Osteosclerosis | 1 | 1982 | 2 | 0.000 |
Why?
|
Anemia, Sideroblastic | 1 | 1982 | 3 | 0.000 |
Why?
|
Pulmonary Embolism | 1 | 1964 | 211 | 0.000 |
Why?
|
Adrenal Glands | 1 | 1982 | 72 | 0.000 |
Why?
|
Agranulocytosis | 1 | 1981 | 30 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1982 | 328 | 0.000 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 1981 | 1 | 0.000 |
Why?
|
Technetium | 1 | 1981 | 11 | 0.000 |
Why?
|
Viral Core Proteins | 1 | 1981 | 21 | 0.000 |
Why?
|
Electrophysiology | 1 | 1982 | 205 | 0.000 |
Why?
|
Creatinine | 1 | 1983 | 485 | 0.000 |
Why?
|
Peripheral Nerves | 1 | 1982 | 67 | 0.000 |
Why?
|
Diphosphates | 1 | 1981 | 17 | 0.000 |
Why?
|
Transferrin | 1 | 1981 | 42 | 0.000 |
Why?
|
Abscess | 1 | 1981 | 73 | 0.000 |
Why?
|
Immune Sera | 1 | 1981 | 88 | 0.000 |
Why?
|
Fluorometry | 1 | 1980 | 19 | 0.000 |
Why?
|
Photomicrography | 1 | 1980 | 7 | 0.000 |
Why?
|
Microscopy, Phase-Contrast | 1 | 1980 | 16 | 0.000 |
Why?
|
Mental Disorders | 1 | 1949 | 1024 | 0.000 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 1980 | 45 | 0.000 |
Why?
|
Substance-Related Disorders | 1 | 1949 | 1019 | 0.000 |
Why?
|
Haplorhini | 1 | 1980 | 57 | 0.000 |
Why?
|
Dermatitis, Exfoliative | 1 | 1980 | 4 | 0.000 |
Why?
|
Purpura | 1 | 1980 | 12 | 0.000 |
Why?
|
Castration | 1 | 1980 | 14 | 0.000 |
Why?
|
Macrophage Migration-Inhibitory Factors | 1 | 1980 | 10 | 0.000 |
Why?
|
Alopecia | 1 | 1979 | 28 | 0.000 |
Why?
|
Receptors, Complement | 1 | 1980 | 120 | 0.000 |
Why?
|
Cocarcinogenesis | 1 | 1979 | 14 | 0.000 |
Why?
|
Chemical Industry | 1 | 1979 | 10 | 0.000 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 1980 | 121 | 0.000 |
Why?
|
Methods | 1 | 1978 | 63 | 0.000 |
Why?
|
Fiber Optic Technology | 1 | 1978 | 17 | 0.000 |
Why?
|
Solvents | 1 | 1979 | 107 | 0.000 |
Why?
|
Hemoglobins | 1 | 1981 | 343 | 0.000 |
Why?
|
Pesticides | 1 | 1979 | 58 | 0.000 |
Why?
|
Mucous Membrane | 1 | 1978 | 122 | 0.000 |
Why?
|
Granulocytes | 1 | 1976 | 79 | 0.000 |
Why?
|
Herpesvirus 3, Human | 1 | 1980 | 398 | 0.000 |
Why?
|
Air Pollutants | 1 | 1979 | 321 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1983 | 2494 | 0.000 |
Why?
|
Hospitals, University | 1 | 1946 | 177 | 0.000 |
Why?
|
Biological Transport | 1 | 1946 | 394 | 0.000 |
Why?
|
Minnesota | 1 | 1964 | 145 | 0.000 |
Why?
|
Students | 1 | 1946 | 576 | 0.000 |
Why?
|